Vista Pharmaceuticals Limited

Equities

524711

INE427C01021

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:56 2024-07-16 am EDT 5-day change 1st Jan Change
15.48 INR +0.06% Intraday chart for Vista Pharmaceuticals Limited -2.03% +5.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Vista Pharmaceuticals Limited Announces Change in Corporate Office Address CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Vista Pharmaceuticals Limited announced that it has received INR 61.895 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Vista Pharmaceuticals Appoints Chairman MT
Vista Pharmaceuticals Limited Announces Executive Changes CI
Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 66.895 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Vista Pharmaceuticals Limited Announces Resignation of Akash Bhagadia as Company Secretary and Compliance Officer CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020 CI
Chart Vista Pharmaceuticals Limited
More charts
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
More about the company